Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure Lowering

Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure Lowering - Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker Exerts Pleiotropic Therapeutic Effects in Addition to Blood Pressure Lowering

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002531

Enrollment

Registered

2009-09-18

Start date

2009-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

This study consisted of a 4-week mono therapy period and 12-week combination therapy period. The patients already being treated with amlodipine, a once-daily 8 mg dose of candesartan was added-on duri

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The eligible subjects were mild-to-moderate essential hypertensive patients who were already treated with a once-daily 5 mg dose of amlodipine monotherapy or with a once-daily 8 mg dose of candesartan monotherapy at the initiation of the monotherapy period and did not achieve the target BP level according to the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009) during the monotherapy period .

Exclusion criteria

Exclusion criteria: Exclusion criteria included patients who exhibited severe hypertension (clinic systolic >= 180 mmHg and/or diastolic BP >= 110 mmHg), renal insufficiency (estimated glomerular filtration < 30 ml/min/1.73 m2), women who were nursing or pregnant, clinically significant heart disease, moderate-to-severe hepatic dysfunction, and known hypersensitivity to any component of the study medications.

Design outcomes

Primary

Measure	Time frame
A. Clinic blood pressure B. Home blood pressure profile C. Renal function including eGFR and urinary protein/albumin excretion. D. Vascular function including central BP, AI, baPWV and ABI.	—

Secondary

Measure	Time frame
1. Glucose metabolism including FPG, IRI, HOMA-IR, HbA1C. 2. Lipid metabolism including T-cho, LDL-cho, HDL-cho, and TG. 3. Activity of sympathetic nerve and renin-angiotensinsystem including PRA, PAC, catecholamine, and urinary angiotensinogen. 4. Oxidative stress marlers including pentosidine and urinary L-FABP. 5. Cardiac function including BNP, cardiac echographic parameters. 6. CBC, electrolyte, and liver function. 7. Adverse events.	—

Measure

Time frame

1. Glucose metabolism including FPG, IRI, HOMA-IR, HbA1C. 2. Lipid metabolism including T-cho, LDL-cho, HDL-cho, and TG. 3. Activity of sympathetic nerve and renin-angiotensinsystem including PRA, PAC, catecholamine, and urinary angiotensinogen. 4. Oxidative stress marlers including pentosidine and urinary L-FABP. 5. Cardiac function including BNP, cardiac echographic parameters. 6. CBC, electrolyte, and liver function. 7. Adverse events.

—

Countries

Japan

Contacts

Public ContactKouichi TAMURA

Yokohama City University School of Medicine Dapartment of Cardiorenal Medicine

tamukou@med.yokohama-cu.ac.jp045-787-2635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026